Established in 2003, X-GEN Pharmaceuticals is a young and flexible organization building on decades of pharmaceutical industry experience offered by the management team. As the healthcare industry changes with increasing speed, the management team is committed to honoring the enduring legacy of its founder, Dan Badia, while having the foresight to embrace the increasingly fast-paced pharmaceutical space to create opportunities for the company and those invested in its success, the employees.
Founded and based in Long Island, New York, privately-held X-GEN continues its original vision and strategy of building a portfolio of products which are long past patent expiration, but still essential to the healthcare community. President and Chief Executive Officer, Susan Badia and the management team have embraced this successful approach while emphasizing a greater commitment to broadening its product portfolio. Ms. Badia stated that X-GEN will continue to concentrate on its “core strengths as we seek products which maintain stable volumes and few competitors. The strong relationships we have throughout the supply chain allow us to maximize market share and logistical efficiencies.”
In addressing X-GEN’s focus on broadening the portfolio of products, Chief Operating Officer, J. Robin Liles adds that “X-GEN’s goal is, ultimately, to add 3 to 5 new products to the company portfolio each year – we are committed to developing a broader line of products.” Liles further stated that “Our typical path toward product development has been to file and own the Abbreviated New Drug Applications (ANDA), but our strategy going forward includes the opportunity for structured partnerships and other agreements which allow X-GEN to leverage its own core competencies and that of its partners. With alliances across the United States and world there is an opportunity to capitalize on existing supply chain expertise to facilitate more rapid product introductions than we have experienced in the past.”
X-GEN Pharmaceuticals is committed to growth and providing affordable, generic equivalents – enhancing patient care today and tomorrow. We will learn from our past, celebrate our victories and embrace our challenges in a rapidly changing environment.
That is who we are.